Close

Explore AI

Explore GPTs

Explore AI News

Explore AI Videos

Explore AI for Jobs

Latest Amgen AI Videos

Find the latest for Amgen company videos

Follow
... 41:44
Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet

TechSurge: Deep Tech VC Podcast

1+ months ago 4K views

AI has made significant strides in drug discovery, particularly through advancements in predicting protein structures and computational design. However, the current hype around AI in creating entirely new therapies is overstated. AI primarily enhances existing proteins rather than generating new therapeutic proteins from scratch. The future of drug discovery will require overcoming data challenges and improving methodologies to create more effective treatments. While progress is being made with technologies like AlphaFold, true breakthroughs in novel drug design remain elusive, and the industry still faces substantial execution challenges in delivering new medications to patients.
17:38 - 17:54

Data scarcity hampers the discovery of novel antibodies due to vast sequence space.

Machine Learning Healthcare
... 9:26
The Role of AI in Personalized Medicine Tailoring Treatments for Every Patient

The Transforming Treatment Institute

1+ months ago 3K views

Personalized medicine, driven by advanced AI technologies, transforms healthcare by tailoring treatments to individual genetic profiles and environmental factors. This approach moves beyond one-size-fits-all practices, enabling predictive analytics for conditions such as heart disease and cancer. AI's power in genomics allows for faster and cheaper sequencing of DNA, assisting in early diagnosis and customized treatment plans. Future advancements promise a shift from reactive to proactive healthcare, empowering patients and doctors alike through continuous data monitoring and tailored interventions, ultimately enhancing survival rates and improving overall health outcomes.
02:38 - 02:42

Genomic profiling with AI identifies mutations for targeted cancer therapies.

Machine Learning Healthcare
... 10:51
Google’s NEW AI Co Scientist is Smarter Than Scientists!

AI Uncovered

1+ months ago 2K views

Google's AI Co-Scientist, powered by Gemini 2.0, is revolutionizing scientific research by not only analyzing data but generating new hypotheses, proposals, and discoveries at unprecedented speed. In fields such as biomedicine, it uncovers solutions faster than human researchers, significantly accelerating the identification of treatments for conditions like cancer and antibiotic resistance. This AI technology allows researchers to collaborate with AI as a partner rather than just a tool, enhancing efficiency while still requiring human oversight for practical application and ethical considerations.
06:27 - 06:38

AI Co-Scientist helps in predicting bacterial resistance mechanisms rapidly.

Google Machine Learning Research & Innovations
... 8:29
IPA Stock - AI Company to Watch (Update)

Blaze Capital

1+ months ago 10K views

Immuno Precise Antibodies (IPA), listed on NASDAQ as IPA, aims to revolutionize healthcare and drug discovery through its patented Lens AI technology. With over 90% of clinical drug developments failing, IPA addresses this challenge by accelerating drug discovery and integrating artificial intelligence with biological data. Their HFT patterns program introduces unique signature sequences, enabling the harmonization of complex biological data. The potential market for AI in drug discovery is projected to be worth $24.6 billion by 2029. The company is making strides in developing precision-targeted treatments, particularly for cancer, enhancing drug efficacy with fewer side effects.
04:01 - 04:06

In silico antibodies targeting tumor proteins show AI's efficacy in drug development.

Immunoprecise Antibodies Ltd Finance
... 22:14
This new AI finds REAL cancer cures & life-saving drugs

AI Search

1+ months ago 22K views

Google's new AI Co-Scientist has achieved significant breakthroughs in drug discovery, including new treatments for leukemia and liver disease, both validated in real-life experiments. This AI system, built with Gemini 2.0, assists scientists by generating novel hypotheses and research proposals, accelerating scientific discoveries. It collaboratively works with human scientists, providing original ideas for complex problems. The AI has demonstrated its capabilities by tackling issues like antibiotic resistance, suggesting candidates quickly compared to traditional research timelines, marking a transformative leap in biomedical research through advanced computational methods.
03:30 - 05:30

AI identifies new targets for liver fibrosis, demonstrating real-world efficacy.

Google Machine Learning Healthcare
... 34:12
Tempus A.I. Stock (TEM) is Crazy! | Deep Analysis on TEM Stock

H Invests

1+ months ago 2K views

Tempus AI focuses on leveraging artificial intelligence to enhance healthcare diagnostics, particularly in oncology. Founded in 2015, it has been using AI and machine learning to analyze laboratory test results in context with patient histories. The CEO discusses how the company aims to improve patient outcomes through personalized treatment plans by utilizing extensive genomic data while also expanding its services to cover various diseases beyond cancer. Despite operating at a loss, Tempus AI is experiencing rapid growth and plans to achieve profitability by 2025, driving significant potential in the healthcare market.
11:24 - 12:02

Tempus AI has a unique position with a database 20 times larger for cancer genomics.

Tempus Machine Learning Finance
... 8:49
Why AMD Stock is a STEAL in the AI Market

Jose Najarro Stocks

1+ months ago 7K views

AMD's recent stock decline highlights concerns over unmet earnings expectations, yet the company's diversification and strength in the AI accelerator market promise potential growth. Despite a cautious approach to AI advancements, AMD's healthy balance sheet and projected revenue growth from varied markets like AI chips and embedded systems create a bullish outlook. The anticipated $6 billion revenue increase reflects solid growth potential, and AMD's current valuations suggest it is undervalued, making it an attractive investment opportunity in the semiconductor sector.
08:02 - 08:06

The AI accelerator market is the main bullish reason for investing in AMD.

AMD AI hardware Finance
... 14:26
AMD is the Next Multi-Trillion $ AI Giant.

Antonio Linares

1+ months ago 7K views

AMD is positioned to emerge as an AI giant with strong fundamentals, bolstered by robust partnerships with major tech companies like Meta and Microsoft. The company's revenue growth has been driven by strategic collaborations and an innovative chiplet platform that enhances product iteration speed and profitability. Despite current skepticism from shareholders due to comparisons with Nvidia, AMD's AI GPU business and data center revenues are set for explosive growth, indicating a significant potential for long-term value creation in the AI sector over the next five years.
04:25 - 04:33

AMD's software advancements allow large-scale deployment with hyperscalers.

AMD AI hardware Tech & Hardware
... 14:26
AMD is the Next Multi-Trillion $ AI Giant.

Antonio Linares

1+ months ago 7K views

AMD is positioned to emerge as an AI giant with strong fundamentals, bolstered by robust partnerships with major tech companies like Meta and Microsoft. The company's revenue growth has been driven by strategic collaborations and an innovative chiplet platform that enhances product iteration speed and profitability. Despite current skepticism from shareholders due to comparisons with Nvidia, AMD's AI GPU business and data center revenues are set for explosive growth, indicating a significant potential for long-term value creation in the AI sector over the next five years.
04:25 - 04:33

AMD's software advancements allow large-scale deployment with hyperscalers.

AMD AI hardware Tech & Hardware